SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

TEMBEXA

EBS·Emergent BioSolutions Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approved June 2021).
Why 4/10
TEMBEXA is already FDA-approved and commercially marketed with no pending regulatory decision (PDUFA, AdComm, or pivotal readout) in the next 12 months. The next catalysts are government contract awards and the mpox trial readout, neither of which is a hard dated binary. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5.
Actionable Insight NEUTRAL

Watch for additional U.S. government (BARDA/ASPR) contract modifications for TEMBEXA stockpiling, which drive the drug's revenue. The mpox clinical trial in Africa (PANTHER study) could open a larger addressable market if results are positive, but that readout has no firm date yet. EBS reports full-year 2026 results in early 2027, which will show whether TEMBEXA deliveries continue to offset declines in other smallpox MCM products.

Price Chart

Loading chart...

Executive Summary

TEMBEXA (brincidofovir) is an FDA-approved oral antiviral for smallpox, cleared in June 2021 under the Animal Rule since human efficacy trials are not feasible for the eradicated disease. Emergent BioSolutions (NYSE: EBS) acquired worldwide rights from Chimerix in September 2022 for $325 million. The drug competes with SIGA Technologies' TPOXX (tecovirimat) in a market driven almost entirely by U.S. and allied government biodefense stockpiling contracts. TEMBEXA is approved for all ages including neonates, a unique label advantage. Emergent has secured multiple government contract modifications totaling over $84 million for TEMBEXA since 2024. However, the drug is a modest part of Emergent's broader portfolio (which includes ACAM2000 vaccine, anthrax products, and naloxone), and the company is under financial strain with Q3 2026 revenue down 52% YoY and a restructuring underway. No near-term binary regulatory catalyst exists for TEMBEXA, making it a steady but unexciting contributor within a challenged company.

How It Works

TEMBEXA is an oral antiviral pill or liquid that stops the smallpox virus from replicating inside human cells. It is a 'prodrug' meaning the body converts it into an active form (cidofovir) after it is swallowed. A lipid (fat) coating helps it get into cells more efficiently and reduces kidney toxicity compared to the older drug cidofovir.

Trial Status

TEMBEXA was approved by the FDA in June 2021 under the Animal Rule, based on efficacy in animal models of smallpox and safety data from human trials in other diseases. The drug is currently being evaluated in a clinical trial for mpox (monkeypox) in Africa, sponsored by PANTHER and the Africa CDC, with Emergent supplying the drug.

The Two-Sided Case

▲ Bull Case5
TEMBEXA is the first and only FDA-approved oral smallpox antiviral for all age groups, including neonates, giving it a unique label advantage over TPOXX.
Emergent has secured multiple government contracts for TEMBEXA: $67.4 million in options (Sept 2024), a $17 million BARDA modification for oral suspension, and ongoing deliveries under a 10-year contract with the U.S. government.
The drug is being evaluated in a clinical trial for mpox (monkeypox) in Africa (PANTHER study), which could expand its addressable market beyond smallpox biodefense.
Analyst consensus is bullish: 5 buy/strong buy ratings vs 1 hold and 1 sell, with a mean price target of $11 (61.5% implied upside from the $6.81 close).
Several large institutional investors added or doubled positions in Q2 2026, including Millennium Management, Goldman Sachs, and Prudential Financial.
▼ Bear Case5
TEMBEXA's smallpox market is almost entirely government stockpiling contracts, which are lumpy and subject to budget timing. Q3 2026 smallpox MCM revenue fell 68% YoY, though TEMBEXA USG sales were higher due to timing.
The drug carries an FDA boxed warning for increased mortality risk when used for longer than the recommended duration, which limits its appeal beyond acute smallpox treatment.
SIGA Technologies' TPOXX (tecovirimat) is the dominant smallpox antiviral with broader government stockpiling contracts globally and a head start (approved 2018 vs TEMBEXA's 2021).
Emergent BioSolutions is in financial distress: Q3 2026 revenue down 52% YoY, GAAP gross margin collapsed to 14%, adjusted EBITDA swung to a loss, and the company cut full-year 2026 guidance to $600-$645 million.
Insider selling in October 2026 (director and SVP sold shares via 10b5-1 plans) and a post-market stock drop to $5.41 (down ~16% from $6.44 close) signal near-term pressure.

Upcoming Catalysts

  • Additional U.S. government (BARDA/ASPR) contract modifications for TEMBEXA stockpiling
  • Readout from the PANTHER mpox clinical trial in Africa (no firm date announced)
  • Emergent's full-year 2026 earnings report (early 2027) showing TEMBEXA revenue contribution

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Emergent BioSolutions Inc. 8-K EBS ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 emergentbiosolutions.com3 biospace.com4 investors.emergentbiosolutions.com5 stockanalysis.com6 en.wikipedia.org7 accessdata.fda.gov8 biospace.com9 siga.com10 sec.gov